Session Title: AMD I
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 08:38
Venue: Hall 1 (Level 2)
First Author: S.Binder AUSTRIA
Co Author(s): I. Krebs L. Schmetterer
Report of an observer and subject masked trial comparing the visual outcome after treatment with Ranibizumab or Bevacizumab in patients with neovascular age-related macular degeneration
Non inferiority study based on the data of MARINA, ANCHOR and FOCUS studies. 320 patients with NV AMD included in this prospective double blinded multicenter trial
Patients with neovascular AMD were randomized to treatment of either 0.5 Ranibizumab or 1,25mg Bevacizumab. After three initial monthly injections eyes patients were treated in a as needed regimen. Monthly assessed best corrected best corrected distance acuity (BCDVA), retinal thickness and adverse events assessment were the main points of interest.
321 patients were randomized, 4 excluded so that a total of 317 eyes were evaluated. BCDVA after one year was equivalent between bevacizumab ( 4.9 letters after 12 months) and ranibizumab (4.1 letters after 12 months). Mean number of treatments was also similar: 5.8x in the ranibizumab group and 6.1x in the bevacizumab group. Retinal thickness measurements showed a decrease of 89.9µm for ranibizumab and 86.3µm for bevacizumab, p=0.81). Serious adverse events were observed in 9.2 % in the ranibizumab group and in 11.6 % in the bevacizumab group.
Bevacizumab was equivalent to ranibizumab at all time points for one year. Neither the total number nor the number of adverse events in any subgroup was significant different.